SCHEMBL4889676

SCHEMBL4889676

FC(F)(F)c1cc(N2CCOCC2)ccc1Nc1ncnc2ccc(-c3cccs3)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.48
MAPT P10636 2/20 0.48
AHR P35869 1/20 0.48
HTT P42858 1/20 0.48
CLK4 Q9HAZ1 4/20 0.47
ALDH1A1 P00352 4/20 0.47
CYP1A2 P05177 3/20 0.47
CYP3A4 P08684 3/20 0.47
TSHR P16473 3/20 0.47
CYP2C19 P33261 3/20 0.47
LMNA P02545 3/20 0.47
TP53 P04637 2/20 0.47
ALOX15 P16050 2/20 0.47
HSD17B10 Q99714 2/20 0.47
HIF1A Q16665 1/20 0.47
USP2 O75604 2/20 0.47
CYP2D6 P10635 2/20 0.47
PI4KB Q9UBF8 1/20 0.47
RIPK2 O43353 1/20 0.47
RIPK3 Q9Y572 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4890249 0.88 CD38 (0.49) MAPK1MAPTAHRHTTCLK4
SCHEMBL4889115 0.85 MAPT (0.66) MAPK1MAPTAHRHTTALDH1A1
SCHEMBL4892764 0.84 MAPT (0.54) MAPK1MAPTAHRHTTCLK4
SCHEMBL4888359 0.76 RIPK2 (0.57) MAPK1MAPTAHRHTTCLK4
SCHEMBL4574615 0.74 PI4KB (0.50) MAPK1MAPTAHRHTTCLK4
SCHEMBL4890852 0.73 EGFR (0.55) MAPK1MAPTAHRHTTCLK4
SCHEMBL4008515 0.73 MAPT (0.80) MAPK1MAPTAHRHTTCLK4
SCHEMBL4573993 0.72 INSR (0.49) MAPK1MAPTAHRHTTCLK4
SCHEMBL4895102 0.71 MAPT (0.63) MAPK1MAPTAHRHTTALDH1A1
SCHEMBL4892645 0.71 PRKDC (0.45) MAPK1MAPTCLK4ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 MAPK1 1945/4885MAPT 2064/4885AHR 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.